KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBT Margin (2018 - 2025)

Historic EBT Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 0.46%.

  • Castle Biosciences' EBT Margin fell 101200.0% to 0.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.51%, marking a year-over-year decrease of 90800.0%. This contributed to the annual value of 6.49% for FY2024, which is 325900.0% up from last year.
  • As of Q3 2025, Castle Biosciences' EBT Margin stood at 0.46%, which was down 101200.0% from 0.17% recorded in Q2 2025.
  • Castle Biosciences' EBT Margin's 5-year high stood at 9.65% during Q3 2024, with a 5-year trough of 91.2% in Q1 2022.
  • Moreover, its 5-year median value for EBT Margin was 18.76% (2021), whereas its average is 26.63%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -724400bps in 2022, then skyrocketed by 660300bps in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' EBT Margin stood at 60.53% in 2021, then increased by 11bps to 53.63% in 2022, then soared by 93bps to 3.84% in 2023, then skyrocketed by 338bps to 9.14% in 2024, then tumbled by -105bps to 0.46% in 2025.
  • Its EBT Margin was 0.46% in Q3 2025, compared to 0.17% in Q2 2025 and 29.86% in Q1 2025.